Solubilized coq-10

Abstract

The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

1 . A solubilized coenzyme Q-10 composition comprising:
 coenzyme Q-10 or an analog thereof;   a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof; and   an acceptable carrier, wherein said composition provides an absorbed percentage of between about 5 percent and about 12 percent coenzyme Q-10 or analog thereof, based on the total amount of said coenzyme Q-10 or analog thereof administered.   
     
     
         2 . The composition of  claim 1 , wherein said coenzyme Q-10 or an analog thereof is selected from the group consisting of coenzyme Q-10, reduced coenzyme Q-10 and semi-reduced coenzyme Q-10. 
     
     
         3 . The composition of  claim 1 , wherein said monoterpene is limonene or a derivative thereof. 
     
     
         4 . The composition of  claim 3 , wherein said limonene derivatives are selected from the group consisting of perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof. 
     
     
         5 . The composition of  claim 1 , wherein said composition is in the form of a solution, an elixir, a suspension, or a capsule. 
     
     
         6 . The composition of  claim 5 , wherein said capsule is a soft gelatin capsule. 
     
     
         7 . The composition of  claim 6 , wherein said carrier is soybean oil. 
     
     
         8 . A solubilized coenzyme Q-10 composition comprising:
 coenzyme Q-10 or an analog thereof;   a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof; and   an acceptable carrier, wherein said composition provides a steady state plasma level concentration of between about 2.5 μg/ml to about 3.5 μg/ml of coenzyme Q-10 or analog thereof.   
     
     
         9 . The composition of  claim 8 , wherein said coenzyme Q-10 or an analog thereof is selected from the group consisting of coenzyme Q-10, reduced coenzyme Q-10 and semi-reduced coenzyme Q-10. 
     
     
         10 . The composition of  claim 8 , wherein said monoterpene is limonene or a derivative thereof. 
     
     
         11 . The composition of  claim 10 , wherein said limonene derivatives are selected from the group consisting of perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof. 
     
     
         12 . The composition of  claim 8 , wherein said composition is in the form of a solution, an elixir, a suspension, or a capsule. 
     
     
         13 . The composition of  claim 12 , wherein said capsule is a soft gelatin capsule. 
     
     
         14 . The composition of  claim 13 , wherein said carrier is soybean oil. 
     
     
         15 . A solubilized coenzyme Q-10 composition comprising:
 coenzyme Q-10 or an analog thereof;   a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof; and   an acceptable carrier, wherein said composition provides a peak plasma level of between about 2.1 μg/ml to about 3.0 μg/ml of coenzyme Q-10 or analog thereof.   
     
     
         16 . The composition of  claim 15 , wherein said coenzyme Q-10 or an analog thereof is selected from the group consisting of coenzyme Q-10, reduced coenzyme Q-10 and semi-reduced coenzyme Q-10. 
     
     
         17 . The composition of  claim 15 , wherein said monoterpene is limonene or a derivative thereof. 
     
     
         18 . The composition of  claim 17 , wherein said limonene derivatives are selected from the group consisting of perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof. 
     
     
         19 . The composition of  claim 15 , wherein said composition is in the form of a solution, an elixir, a suspension, or a capsule. 
     
     
         20 . The composition of  claim 19 , wherein said capsule is a soft gelatin capsule. 
     
     
         21 .- 27 . (canceled)